Stockreport

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022

Kronos Bio, Inc.  (KRON) 
PDF SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affec [Read more]